Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to -$897000.0.

  • Pliant Therapeutics' Change in Account Payables fell 12406.76% to -$897000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 28150.14%. This contributed to the annual value of $1.4 million for FY2024, which is 5190.3% down from last year.
  • As of Q3 2025, Pliant Therapeutics' Change in Account Payables stood at -$897000.0, which was down 12406.76% from -$4.2 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Change in Account Payables ranged from a high of $3.7 million in Q3 2024 and a low of -$4.2 million during Q2 2025
  • For the 5-year period, Pliant Therapeutics' Change in Account Payables averaged around -$81052.6, with its median value being $52000.0 (2022).
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 216315.79% in 2022, then soared by 193653.85% in 2023.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Change in Account Payables stood at $490000.0 in 2021, then tumbled by 427.55% to -$1.6 million in 2022, then soared by 173.02% to $1.2 million in 2023, then tumbled by 179.35% to -$930000.0 in 2024, then grew by 3.55% to -$897000.0 in 2025.
  • Its last three reported values are -$897000.0 in Q3 2025, -$4.2 million for Q2 2025, and -$338000.0 during Q1 2025.